LRRC15 and neoplasm: Moreover, ABBV-085, a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) designed to target against LRRC15, has shown significant anti-tumor activity in several LRRC15 stromal-positive or cancer-positive models [7].